GLP-1 Side Effects: The Nausea, the Hair-Loss Question, and What's Actually Serious

What are the most common GLP-1 side effects?

Every GLP-1 slows how fast your stomach empties. It also turns down hunger signals in the brain. That holds for brand-name drugs and for compounded ones, which a pharmacy mixes and the FDA has not approved. Nearly every common side effect traces back to those two actions.

Nausea leads the list. In Wegovy's weight-loss trials, 44% of people had nausea, versus 16% on placebo, a dummy treatment, per its FDA label. In Zepbound's trials, it was 25% to 29% depending on the dose, versus 8% on placebo, per its FDA label. The trials were different, so these numbers don't rank the two drugs.

• Nausea. The most common complaint, usually strongest right after a dose increase.
• Vomiting. Less common than nausea, and more likely early on.
• Diarrhea or constipation. Some people get both, at different times. On Wegovy, 30% had diarrhea, versus 16% on placebo. On Zepbound, it was 19% to 23%, versus 8%.
• Belly pain, bloating or reflux. Reflux is stomach acid rising into your throat.
• Tiredness, headache or mild dizziness. These show up more when you are eating much less than usual.
• Redness or irritation where you inject. This applies to the shots only.

None of this means something has gone wrong. It is the drug doing what it was built to do. It is also why every GLP-1 starts at a low dose and climbs slowly. For figures on one drug, see the Ozempic, Wegovy, Zepbound, semaglutide or tirzepatide side-effect guides.

Does GLP-1 cause hair loss?

It can, though not by acting on your hair directly. The Wegovy and Zepbound labels both say hair loss in their trials was linked to weight loss. The usual pattern is telogen effluvium, a temporary shedding all over the scalp. Fast weight loss pushes many hairs into a resting phase at the same time. A few months later, those hairs fall out together. Eating less, and less protein, is thought to add to it.

Women report it more often than men. In Zepbound's main trials, 7.1% of women had hair loss, versus 1.3% of women on placebo. In Wegovy's trials, it was 4% of women, versus 2% on placebo. Shedding tends to start a few months after the weight comes off, not when you start the drug. For most people it eases once weight steadies and eating returns to normal.

If perimenopause is already thinning your hair, the two can stack. Perimenopause hair loss covers that side. Ozempic's side-effect guide looks closer at the shedding data for one drug.

How do you manage the common side effects?

A few habits cover most of what shows up in the first weeks, whichever GLP-1 you take.

• Keep to the dose schedule. Dose increases are spaced out to give your gut time to adjust. Moving faster tends to backfire.
• Eat smaller, lower-fat meals. A large or fatty meal on a slowed stomach is the most common nausea trigger.
• Drink enough fluids. This matters most during a stretch of vomiting or diarrhea.
• Protect the empty-stomach window on a semaglutide pill. Food or drink too soon after the pill cuts how much you absorb.
• Notice your timing. Some people do better taking their dose at a set time once they see when nausea peaks.

What are the serious side effects, and does GLP-1 cause cancer?

A shorter list sits below the everyday stomach complaints. These problems are less frequent. They are the reason for the warnings on the labels.

• Pancreatitis. This is swelling of the pancreas, the organ behind the stomach that helps digest food. It is uncommon but has been seen across the drug class. The labels say to stop the drug if it is suspected.
• Gallbladder disease. Gallstones and an inflamed gallbladder show up more often than on placebo. The labels link this to weight loss, but say it can also happen without fast weight loss.
• Thyroid C-cell tumors. Semaglutide and tirzepatide caused these tumors in rats and mice. It is not known whether they do the same in people. That is why the labels carry a boxed warning, the FDA's strongest kind. People with a personal or family history of medullary thyroid cancer, or a gene condition called MEN 2, should not take them.

On the wider cancer question, the research so far is reassuring. A 2024 study in the BMJ followed about 145,000 people taking a GLP-1 in three Nordic countries. Over about four years, it found no clear rise in thyroid cancer compared with another diabetes drug.

Pancreatic cancer came up as a question more than a decade ago. In 2014, the FDA and European regulators reviewed the data and found it did not support a causal link. Researchers keep watching both cancers as more years of use build up.

Which side effects need same-day medical attention?

Everyday nausea and bloating are one thing. The signs below are different, because they can point to one of the serious risks. This list follows the warnings in the Wegovy and Zepbound labels. These signs should not wait for a routine follow-up message.

• Severe belly pain that won't go away. It sometimes spreads to your back, with or without vomiting. It can be a sign of pancreatitis.
• Pain in the upper right belly, fever, or yellow skin or eyes. These can point to the gallbladder.
• A new lump in your neck, lasting hoarseness, or trouble swallowing or breathing. The labels name these as possible thyroid tumor signs.
• Signs of serious dehydration. Look for very little urine, dizziness when you stand, or confusion. This matters most after days of vomiting or diarrhea.
• Signs of very low blood sugar if you also take insulin or a sulfonylurea, a type of diabetes pill. Look for shakiness, sweating or confusion that food doesn't fix.
• Swelling of the face, lips or throat, or trouble breathing. The labels list serious allergic reactions.

Mood questions also circulated widely. In January 2026, the FDA finished its review of suicidal thoughts and GLP-1 drugs. It looked at 91 placebo-controlled trials and a large insurance-claims study in people with type 2 diabetes. It found no increased risk. It then asked the makers to remove that warning from the Wegovy, Zepbound and Saxenda labels. Still, new low mood or thoughts of self-harm deserve a call right away, whatever the cause.

Is GLP-1 actually safe?

For most adults, yes, with the warnings above in mind. The common side effects are frequent but usually manageable. The serious ones are uncommon.

Which drug you take, and why, also matters. Ozempic and Mounjaro are FDA-approved for type 2 diabetes. Wegovy and Zepbound use the same two molecules and are approved for weight management. Prescribing Ozempic or Mounjaro for weight loss without diabetes is off-label, meaning a use the FDA has not approved.

Off-label does not mean untested. The same molecules were studied for weight loss under the Wegovy and Zepbound names, and the side effects carry over. What often does not carry over is insurance. Plans regularly deny coverage for an off-label use.

A few situations call for extra care, according to the labels:

• Birth control pills. Zepbound and Foundayo can make them work less well. Their labels advise switching to a non-pill method, or adding a barrier method like condoms. Do this for about a month after you start and after each dose increase.
• Planning a pregnancy. The Wegovy label says to stop at least two months before trying, because semaglutide stays in the body a long time.
• Surgery or sedation coming up. Tell the care team you take a GLP-1. A slowed stomach raises the risk of breathing in food under anesthesia.
• Severe gastroparesis, a stomach that empties very slowly. The Wegovy label does not recommend the drug for it.

Does GLP-1 cause muscle loss?

Yes, to some degree. Part of the weight lost on a GLP-1 is lean mass, which includes muscle, rather than fat. Body-composition studies inside the big weight-loss trials showed this for both semaglutide and tirzepatide. It matters more after 40, because perimenopause already chips away at muscle. GLP-1s and muscle loss in perimenopause covers the research, whether the two drugs differ, and what protects muscle.

What are the long-term side effects of GLP-1s?

Semaglutide has been prescribed since 2017 and tirzepatide since 2022. That gives years of safety data in people with type 2 diabetes. Use for weight loss is newer, often at higher doses and for longer. Some long-term questions are still open:

• How years of weight loss affect bone and muscle
• Whether the rodent thyroid finding means anything for people over many years
• What happens to weight and metabolism after you stop

One big question has an answer. Semaglutide's SELECT trial followed people with heart disease and overweight or obesity, without diabetes, for several years. It found fewer major heart events, such as heart attacks and strokes, than on placebo.

SELECT also found a bone signal that is now on Wegovy's label. Hip and pelvis fractures affected 1% of women on semaglutide, versus 0.2% on placebo. None of the open questions points to a hidden danger. They reflect a weight-loss use that is younger than the diabetes one.

Do GLP-1 pills have different side effects than injections?

The side-effect list is much the same, because the drug acts on the same receptor either way. What changes is how it gets into your body.

Semaglutide comes as the Wegovy pill, approved in December 2025, and the Ozempic pill, sold as Rybelsus until May 2026. Only about 1% to 2% of a Wegovy pill dose reaches your blood, versus 89% for the shot, per the Wegovy label. So the pill comes with strict rules. You take it on an empty stomach with up to 4 ounces of water. Then you wait at least 30 minutes before eating, drinking or taking other medicines.

A daily pill gives a small dose each day instead of one weekly peak. Some people find that gentler on the stomach. The timing rules take their own getting used to.

Foundayo works differently. It is orforglipron, a GLP-1 pill from Lilly that is not built like the gut hormone, approved for weight loss on April 1, 2026. You can take it with or without food. It carries the same pancreatitis and stomach warnings. It also carries the thyroid boxed warning, even though orforglipron did not cause tumors in rodents.

Semaglutide vs. tirzepatide: is one easier to tolerate?

No one can say for sure yet. Tirzepatide also acts on a second hormone receptor, called GIP. Some researchers think that may soften nausea, but the idea rests mostly on lab research.

The only head-to-head trial so far, SURMOUNT-5, found stomach side effects were the most common in both groups. Most were mild to moderate and came during dose increases. Which drug sits easier with your gut is often something you learn by trying it. A provider can slow the dose steps if it feels rough.

Where to get help if a side effect isn't settling

If a symptom drags past the first few months, providers differ most in what's included. Labs, coaching and insurance help matter more here than the sticker price.

• [Ro](/reviews/ro/): the most structured monitoring. A metabolic lab test at Quest is part of the membership when your provider orders it. Extra tests cost more. Insurance help is included too. Ro prescribes only FDA-approved brand-name drugs, such as Wegovy, Zepbound and Foundayo. Membership about $150/mo · First month $39 · About $75–$100/mo prepaid · Medicine extra, from about $150/mo
• [PlushCare](/reviews/plushcare/cost/): best if you have insurance. It bills your plan for visits, and PlushCare says most in-network patients pay $30 or less a visit. Without insurance, a visit costs about $130. Copays help if you expect several follow-ups.
• [Mochi Health](/reviews/mochi-health/): a lower monthly price. Its care team includes doctors board-certified in obesity medicine. It sells compounded semaglutide and tirzepatide, and can prescribe brand-name drugs at a separate price. Labs are not included. Semaglutide about $140/mo at the starting dose · Tirzepatide about $170/mo · Rises with the dose, up to about $270 and $280 · $79 membership included · First month of membership free, not in every state
• [Henry Meds](/reviews/henry-meds/): one bundled price, no membership. Visits, medicine and shipping come in one monthly price, which varies with your dose. Labs are not part of the plan. It sells compounded semaglutide as a shot or tablet, and tirzepatide as a tablet. From about $250/mo · About $150–$200/mo with a year prepaid
• [Fridays](/reviews/fridays/): diet support built in. A dietitian and coaching are included, a real help if nausea or appetite changes are what you're managing. It sells compounded semaglutide and tirzepatide. Semaglutide about $280/mo month to month · About $150/mo with a year paid upfront · Fees are not refundable if you cancel mid-plan